NORTHERN TRUST CORP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 132 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$13,042,278
-21.2%
473,920
-2.8%
0.00%0.0%
Q2 2023$16,549,425
-4.3%
487,752
+1.5%
0.00%0.0%
Q1 2023$17,290,297
-10.7%
480,553
+10.6%
0.00%
-25.0%
Q4 2022$19,370,656
+63.2%
434,612
+2.9%
0.00%
+33.3%
Q3 2022$11,869,000
+3.9%
422,241
-0.3%
0.00%
+50.0%
Q2 2022$11,422,000
-23.7%
423,667
-3.6%
0.00%
-33.3%
Q1 2022$14,970,000
-16.5%
439,534
-5.3%
0.00%0.0%
Q4 2021$17,936,000
-27.6%
464,164
+1.1%
0.00%
-25.0%
Q3 2021$24,788,000
+79.8%
459,113
+11.4%
0.00%
+100.0%
Q2 2021$13,786,000
+524.1%
412,263
+284.6%
0.00%
Q1 2021$2,209,000
+32.8%
107,206
+12.9%
0.00%
Q4 2020$1,664,000
+26.9%
94,989
+7.5%
0.00%
Q3 2020$1,311,000
+76.2%
88,345
+54.2%
0.00%
Q2 2020$744,000
+1205.3%
57,300
+67.3%
0.00%
Q1 2020$57,000
-26.9%
34,260
-0.9%
0.00%
Q4 2019$78,000
+23.8%
34,581
+17.5%
0.00%
Q3 2019$63,000
-18.2%
29,427
+1.8%
0.00%
Q2 2019$77,000
-44.6%
28,898
+2.4%
0.00%
Q1 2019$139,00028,2100.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders